Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

pregnancy (see complete product information). Adverse events reported in more than 30% of renal, cardiac or liver transplant patients receiving CellCept (in combination with cyclosporine and corticosteroids) were pain, fever, headache, asthenia, anemia, leucopenia (patients should be monitored for neutropenia; dosing should be interrupted or the dose reduced if neutropenia develops), thrombocytopenia, leukocytosis, urinary tract infection, hypertension, hypotension, peripheral edema, hypercholesteremia, hypokalemia, hyperglycemia, creatinine, BUN and cough increased, hypomagnesemia, diarrhea, constipation, nausea, vomiting, respiratory infection, dyspnea, lung disorder, pleural effusion, tremor and insomnia. Patients receiving immunosuppressant regimens are at increased risk of developing lymphomas and other malignancies, particularly of the skin.

Warning: Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

About Aspreva Pharmaceuticals

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at http://www.aspreva.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's lead
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/30/2014)... 30, 2014  The number of retail health clinics ... growing steadily, thanks to drug store chains, according to ... the economic downturn, retail clinic growth had been at ... as the number of retail clinics reached nearly 1,600 ... Clinics Market Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)...  Nektar Therapeutics (Nasdaq: NKTR ) will ... September 30, 2014 on Thursday, November 6, 2014, after ... , president and chief executive officer, will host a ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... Webcast of the conference call can be accessed through ...
(Date:10/30/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Wednesday, November 5, 2014 ... management will hold a conference call at 7:30 a.m. ... 8:30 p.m., Beijing Time on November 6, 2014, to ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2China Biologic to Report Third Quarter 2014 Financial Results 2
... Denmark and SEATTLE, May 2, 2011 CMC ... operations in Copenhagen, Denmark and Seattle, Washington USA, ... to serve at its Chief Executive Officer. CMC ... to delivering  world class, fully integrated, biopharmaceutical process ...
... Anticipating record attendance among the investment community at the ... 10-11 at the Marriott Resort in Ypsilanti, Mich., event organizers ... for funding at this year,s event. The 41 presenting ... were selected from a competitive pool of 85 applications.  During ...
Cached Medicine Technology:CMC Biologics Announces Appointment of New CEO 2Michigan Growth Capital Symposium Unveils Robust Line Up of Presenting Companies for 30th Anniversary Event 2Michigan Growth Capital Symposium Unveils Robust Line Up of Presenting Companies for 30th Anniversary Event 3
(Date:10/30/2014)... and her research group at the DFG Research Center ... the TU Dresden (CRTD) demonstrated for the first time ... cord in three dimensions from mouse embryonic stem cells. ... interneurons along the dorsal/ventral axis was observed., This study ... " Stem Cell Reports " on 30.10.2014 ., For ...
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... law firm files notice of claim against City of New York ... ... NY (Lexis Nexis) August 28, 2008 -- http://thesandersfirm.com/attorney.asp?attorneyid=14 [Marc ... Sanders, Sanders, Block, Woycik, Viener & Grossman, P.C. in Bronx, New ...
... Efforts to Create Sensible Fire Safety ... Legislation, ... voted to maintain California,s tough fire,standards by striking down proposed fire retardant ... sensible,legislation to address fire safety regulations in the state. The bill would,have ...
... gain access to innovative medical, education and news ... radio channel created for medical professionals by medical ... 157 announced today a new,strategic programming partnership with ... and largest, independent,association for physicians-in-training., Gary Epstein, ...
... American Society for Therapeutic Radiology and Oncology has selected ... honorary member. Dr. Evans will be recognized during the ... during ASTRO,s 50th Annual Meeting in Boston., Dr. Evans ... study of childhood cancer for decades. She was one ...
... cuts risk in half, study finds , , WEDNESDAY, Aug. 27 ... of preterm delivery, cut the rate of cerebral palsy in ... "If deemed to be at high or immediate risk of ... consider using magnesium sulfate to prevent their child from having ...
... treating ,wet, form of the eye disease , , WEDNESDAY, ... States and China have identified the first gene directly ... one of two forms of age-related macular degeneration that ... older Americans. , The discovery, based on work with ...
Cached Medicine News:Health News:New York-Based Sanders Law Firm Files Claim for Good Samaritan Beaten by New York City Police Officers 2Health News:California Senate Rejects Proposed Effort to Weaken Fire Safety Standards 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
The Chalam Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens. This lens was developed with K.V. Chalam,...
... patented ACS lenses offer the high resolution, ... the original clariVits. The simple two part ... its integrity during surgery. Simply autoclave, add ... then lock together for use. (ACS) AutoClave ...
... With somewhat higher magnification and ... is best suited for detailed ... The Central Retinal is ideal ... in membrane peeling in proliferative ...
Medicine Products: